12:00 AM
Feb 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Elaprase idursulfase: Phase I/II data

Top-line data from an open-label, U.S. and U.K. Phase I/II trial in about 16 Hunter Syndrome patients with CNS symptoms showed that once-monthly 1, 10 and 30 mg doses of intrathecal idursulfase were well tolerated and led to a...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >